← Teva Pharma Industries Ltd ADR overview

Teva Pharma Industries Ltd ADR vs Biogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Teva Pharma Industries Ltd ADR (TEVA)

Q3 2026
▲3

Teva Q3: Pipeline Expansion, Guidance Raise, Debt Cut, But Pricing Risks Loom

  • Pipeline Expansion and Strategic Deals Teva acquired BioXcel, gained FDA acceptance for an Entyvio biosimilar, advanced Phase 3 duvakitug, and signed a Samsung Bioepis biosimilar deal, broadening its pipeline and biosimilar portfolio.

    These moves expand Teva's future revenue sources and support its Pivot to Growth strategy.

  • Strong Sales Drive Guidance Raise Robust sales of AUSTEDO, AJOVY, and UZEDY led to a $75 million guidance raise and a Q2 revenue beat, showcasing the strength of Teva's branded drug portfolio.

    This directly reflects better-than-expected financial performance and improved outlook.

  • Debt Reduction and Listing Upgrade Teva completed a $4.9 billion refinancing, secured investment-grade ratings early, and replaced ADRs with a direct NYSE listing, strengthening its balance sheet and market presence.

    These actions improve financial flexibility and may attract a broader investor base.

  • Margin Targets vs. Pricing Pressures Management targets ~55% gross and 30% operating margins by 2027 with $700 million in cost savings, but Medicaid cuts and most-favored-nation pricing threaten revenue, and adjusted EPS missed estimates.

    This highlights the tension between ambitious profitability goals and external pricing challenges.

September 2026
▲4

Teva's Growth Pivot Accelerates with Pipeline, Cost Cuts, and New Deals

  • Teva's 'Pivot to Growth' Strategy Accelerates Teva said its growth strategy is accelerating, with debt cut, investment-grade ratings secured ahead of plan, and raised sales targets for key drugs like AUSTEDO and AJOVY. This boosts confidence in future revenue and earnings, supporting a higher stock price.

    This is a major update on Teva's strategic progress, directly impacting investor confidence and future growth prospects.

  • New Schizophrenia Data Supports Potential Blockbuster New Phase 3 data for TEV-'749, a long-acting schizophrenia treatment, showed high stabilization and low relapse rates. With an FDA decision expected soon, this could become a significant new product, driving future revenue and stock gains.

    This is new clinical data that de-risks a key pipeline asset and highlights near-term regulatory catalyst.

  • CEO Details Margin Expansion and Cost Savings Teva's CEO outlined a plan to expand gross margin to ~55% and achieve a 30% operating margin by 2027, backed by $700 million in cost savings. The innovative business grew 40% in Q2, showing the strategy is working and boosting profitability outlook.

    This provides concrete financial targets and evidence of margin improvement, key drivers for earnings and stock valuation.

  • Teva Expands Biosimilar Pipeline with Samsung Bioepis Deal Teva signed a global deal with Samsung Bioepis for up to six biosimilar candidates, adding to its pipeline. This expands Teva's biosimilar portfolio and commercial reach, supporting long-term growth in a high-margin area.

    This is a new partnership that strengthens Teva's biosimilar business, a key growth driver.

Latest
▲4

Teva's Growth Pivot Accelerates with Pipeline, Cost Cuts, and New Deals

  • Teva's 'Pivot to Growth' Strategy Accelerates Teva said its growth strategy is accelerating, with debt cut, investment-grade ratings secured ahead of plan, and raised sales targets for key drugs like AUSTEDO and AJOVY. This boosts confidence in future revenue and earnings, supporting a higher stock price.

    This is a major update on Teva's strategic progress, directly impacting investor confidence and future growth prospects.

  • New Schizophrenia Data Supports Potential Blockbuster New Phase 3 data for TEV-'749, a long-acting schizophrenia treatment, showed high stabilization and low relapse rates. With an FDA decision expected soon, this could become a significant new product, driving future revenue and stock gains.

    This is new clinical data that de-risks a key pipeline asset and highlights near-term regulatory catalyst.

  • CEO Details Margin Expansion and Cost Savings Teva's CEO outlined a plan to expand gross margin to ~55% and achieve a 30% operating margin by 2027, backed by $700 million in cost savings. The innovative business grew 40% in Q2, showing the strategy is working and boosting profitability outlook.

    This provides concrete financial targets and evidence of margin improvement, key drivers for earnings and stock valuation.

  • Teva Expands Biosimilar Pipeline with Samsung Bioepis Deal Teva signed a global deal with Samsung Bioepis for up to six biosimilar candidates, adding to its pipeline. This expands Teva's biosimilar portfolio and commercial reach, supporting long-term growth in a high-margin area.

    This is a new partnership that strengthens Teva's biosimilar business, a key growth driver.

August 2026
▲3▼1

Teva's pipeline and branded drugs shine despite pricing headwinds

  • Pipeline expansion and regulatory wins Teva agreed to acquire BioXcel's IGALMI and BXCL501, the FDA accepted a subcutaneous Entyvio biosimilar, and duvakitug entered Phase 3 with $2-5 billion peak sales potential. These moves strengthen Teva's pipeline and future growth prospects.

    These pipeline advancements are new and directly support Teva's long-term growth story.

  • Strong financial performance and guidance raise Teva raised 2026 revenue guidance by $75 million on AUSTEDO, AJOVY, and UZEDY strength, and Q2 sales beat at $4.1 billion. This shows the branded drug strategy is delivering results.

    The guidance increase and sales beat are new and highlight Teva's improving financial performance.

  • Balance sheet improvement and listing change Teva completed a $4.9 billion debt refinancing that lowered interest costs and replaced its ADRs with a direct NYSE listing. These actions reduce expenses and simplify trading for investors.

    These are new capital structure changes that benefit Teva's financial health and investor accessibility.

  • Pricing pressures and earnings miss Medicaid price cuts and most-favored-nation pricing may pressure revenue, and adjusted EPS missed estimates. The BioXcel deal initially pushed shares down 1%, reflecting investor concerns.

    These are new negative factors that could weigh on Teva's stock price.

▲4

Teva's Branded Drug Push and Debt Refinancing Drive Gains

  • Duvakitug Phase 3 Potential Teva's duvakitug, co-developed with Sanofi, is entering Phase 3 trials for ulcerative colitis and Crohn's disease after strong Phase 2b results. Analysts project peak annual sales of $2–5 billion, which could fuel another 50% stock rally. This pipeline success supports future revenue growth and investor optimism.

    This is a new pipeline catalyst that could significantly boost Teva's long-term revenue and stock price.

  • Raised 2026 Revenue Guidance Teva raised its 2026 revenue midpoint by $75 million, driven by strong sales of AUSTEDO, AJOVY, and UZEDY. Combined revenue for these three drugs is now expected at about $3.7 billion. This shows Teva's branded drug strategy is working and boosts confidence in future earnings.

    This is a new guidance raise that directly reflects stronger-than-expected demand for Teva's key products.

  • Direct NYSE Listing and Q2 Sales Beat Teva will replace its ADRs with common stock listed directly on the NYSE starting September 14, which could attract more institutional and retail investors. Q2 sales of $4.1 billion beat estimates, though adjusted EPS missed. The listing change and sales beat drove a 12.3% weekly gain.

    This is a new capital markets event that improves liquidity and investor access, supporting the stock price.

  • $4.9B Debt Refinancing Teva priced $4.9 billion in new senior notes to refinance higher-cost debt, lowering interest expenses. The new notes carry lower coupons than the debt being redeemed, which will improve cash flow and profitability. This strengthens Teva's balance sheet and supports earnings growth.

    This is a new financing action that reduces interest costs and improves financial flexibility, directly benefiting the stock.

▲2

Teva Buys BioXcel Assets, Expands Biosimilar, Accepts Medicaid Price Cuts

  • Teva to acquire BioXcel's IGALMI and BXCL501 assets out of bankruptcy Teva is the stalking horse bidder for BioXcel's assets, including IGALMI and a potential at-home agitation treatment. This adds a commercial drug and a late-stage product to Teva's portfolio, which can boost future revenue. The market initially sent Teva shares down 1%, but the long-term growth potential is positive.

    This is a new acquisition that expands Teva's product portfolio and could drive future revenue.

  • FDA accepts Alvotech's BLA for subcutaneous Entyvio biosimilar, partnered with Teva Alvotech's application for a subcutaneous version of Entyvio, a treatment for ulcerative colitis and Crohn's disease, has been accepted by the FDA. Teva will commercialize it if approved. This advances Teva's biosimilar pipeline, offering a new revenue stream and strengthening its competitive position in immunology.

    This regulatory milestone for a partnered product expands Teva's biosimilar offerings and future sales potential.

  • Teva agrees to Medicaid price cuts and MFN pricing in exchange for tariff relief Teva joined nine other drugmakers in deals to lower Medicaid drug prices to match foreign prices, and to supply 45 tons of metronidazole to the government stockpile. In return, Teva gets relief from import tariffs on pharmaceutical ingredients. The price cuts may pressure revenue, but tariff relief and regulatory clarity are positives.

    This is a major new regulatory and pricing agreement that directly affects Teva's revenue and costs.

Q2 2026
▲4

Teva's branded drug push and biosimilar deals drive growth outlook

  • Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

    This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

  • Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

    This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

  • European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

    New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

  • Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

    This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

June 2026
▲4

Teva's branded drug push and biosimilar deals drive growth outlook

  • Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

    This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

  • Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

    This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

  • European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

    New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

  • Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

    This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

▲4

Teva's branded drug push and biosimilar deals drive growth outlook

  • Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

    This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

  • Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

    This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

  • European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

    New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

  • Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

    This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

Biogen Inc (BIIB)

Q3 2026
▼3▲1

Biogen's mixed quarter: Leqembi approvals offset trial miss and guidance cut

  • Leqembi approvals expand access The FDA approved at-home subcutaneous Leqembi, and China and Japan approved injections, making the Alzheimer's drug easier to use. Leqembi sales rose 15% to about $184 million, helping Q2 results beat expectations.

    This is a key positive development that drove investor optimism and revenue growth.

  • Diranersen trial failure Biogen's experimental drug diranersen missed its main trial goal, causing shares to drop 9%. This setback raised concerns about the company's pipeline and future growth prospects.

    This was a major negative event that directly impacted the stock price.

  • Guidance cut on acquisition charges Biogen cut its 2026 earnings guidance to $12–$13 per share due to about $3.85 per share in acquisition charges, including from the $5.6 billion Apellis buyout. This lowered profit expectations.

    The guidance cut is a significant negative factor that weighed on the stock.

  • Medicare pricing pressure on ZURZUVAE Medicare pricing pressure may limit the launch of ZURZUVAE, and Biogen is restricting it to a few European countries. This could slow the drug's uptake and revenue potential.

    This highlights a regulatory and pricing challenge that could hinder growth.

August 2026
▲3▼1

Biogen expands Alzheimer's reach but pricing and competition weigh

  • RayThera acquisition adds immunology drug Biogen acquired RayThera, gaining an early-stage immunology drug. This adds a new potential treatment to its pipeline, showing progress in building future growth beyond its current medicines.

    New acquisition expands pipeline, a key positive development in the period.

  • China and Japan approve at-home Leqembi injections China and Japan approved at-home under-the-skin Leqembi injections, making Alzheimer's treatment easier and expanding the market. This could boost sales and patient access in key regions.

    Geographic expansion of Leqembi is a new positive catalyst for demand.

  • Ten Phase 3 programs promise growth Biogen has ten late-stage programs in development, which could drive future growth as its multiple sclerosis revenue shrinks. This shows a strong pipeline to replace older products.

    Pipeline strength is a forward-looking positive not previously highlighted.

  • Medicare pricing pressure may limit ZURZUVAE launch Medicare pricing pressure could hurt the launch of ZURZUVAE, and Biogen is limiting it to a few European countries. This adds risk to a key new product's sales potential.

    New pricing and launch risk for ZURZUVAE is a negative factor.

Latest
▲3▼1

Biogen's pipeline push and Leqembi rollout drive gains, but pricing risks loom

  • 10 Phase III programs signal growth beyond MS Biogen said it has 10 late-stage trials with results starting in Q4, shifting focus from its shrinking MS business to new drugs like LEQEMBI and ZURZUVAE. This raises hopes for future revenue growth, supporting the stock.

    This is the main new strategic update that could drive long-term growth and investor optimism.

  • Japan approves at-home Leqembi injection Japan cleared a subcutaneous form of Leqembi, allowing weekly at-home dosing instead of hospital infusions. This is the third country to approve it, making the Alzheimer's drug easier to use and expanding its market, which could boost sales.

    New regulatory approval directly expands the addressable market for a key growth drug.

  • Medicare price crackdown may limit Zurzuvae launch A study warns that U.S. efforts to align Medicare drug prices with cheaper countries could push companies to raise prices or withdraw medicines elsewhere. Biogen's CEO said Zurzuvae will launch in only a few European countries to offset lost U.S. revenue, signaling a hit to its global sales potential.

    This is a new regulatory risk that could reduce future revenue from a key product.

  • Biogen posts best quarterly revenue beat in group Biogen's Q2 revenue of $2.74 billion rose 3.4% and beat expectations by 12.1%, the strongest among 11 therapeutics stocks. This shows better-than-expected commercial execution, which can lift investor confidence.

    New earnings data confirms strong performance relative to peers, a positive fundamental signal.

▲3

Biogen's mixed quarter: raised revenue, cut EPS, new China approval

  • RayThera acquisition closes, EPS guidance cut Biogen completed its purchase of RayThera, adding an early-stage immunology drug. But acquisition charges forced it to slash 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25. The revenue outlook rose to mid-single-digit growth, but the profit hit is what investors will feel near-term.

    This is the single biggest new event, directly changing Biogen's earnings outlook and explaining the stock's mixed reaction.

  • China approves at-home LEQEMBI injection China approved a subcutaneous (under-the-skin) form of LEQEMBI for early Alzheimer's, allowing weekly at-home dosing instead of hospital infusions. This is the second country to clear it, after the U.S. in July. It widens the market and makes treatment far easier for patients.

    A new regulatory approval in a huge market (17 million early Alzheimer's patients in China) directly boosts the long-term sales potential of Biogen's key Alzheimer's drug.

  • Five Phase 3 readouts ahead; shares seen as undervalued Biogen raised its non-GAAP EPS guidance and has five late-stage trial results coming in lupus, transplant and rare diseases. Shares trade about 10% below the average analyst target, with a 54% one-year total return. But competition in MS and Alzheimer's, plus launch risks for LEQEMBI and ZURZUVAE, remain real concerns.

    This gives the forward-looking catalyst picture and the valuation gap, which is central to why investors are watching Biogen now.

  • Biogen adopts Veeva's AI-powered CRM globally Biogen selected Veeva's Vault CRM suite, an AI-driven sales and safety platform, for global use. This is an operational upgrade, not a direct revenue driver, but it signals Biogen is investing in modern commercial infrastructure. It also deepens a multi-year software relationship, which can lower long-term selling costs.

    It shows Biogen is modernizing its commercial operations with AI, a modest but real positive for efficiency and execution.

July 2026
▲2▼2

Biogen's mixed July: Leqembi wins, diranersen disappoints, guidance cut

  • FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, an at-home under-the-skin version of Biogen's Alzheimer's drug. This should make treatment easier and more convenient, potentially boosting demand and future sales.

    This is a new regulatory approval that could drive future revenue growth.

  • Q2 results beat on rare-disease and Leqembi demand Biogen's second-quarter results beat expectations, helped by strong demand for rare-disease drugs and Leqembi, with Leqembi sales up 15% to about $184 million. This shows the company's newer products are gaining traction.

    This is new financial data showing better-than-expected performance.

  • Diranersen trial misses goal, shares drop 9% Biogen's experimental Alzheimer's drug diranersen missed its main trial goal, with a puzzling result: the lowest dose worked best while higher doses did worse. The failure sent shares down about 9%.

    This is a major clinical setback that directly hurt the stock.

  • 2026 earnings guidance cut on acquisition charges Biogen lowered its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, due to about $3.85 per share in acquisition charges, including 85 cents from the $5.6 billion Apellis buyout.

    This is a new guidance cut that weighs on investor expectations.

▲3▼1

Biogen beats on drug demand but cuts 2026 profit outlook

  • Q2 beat on rare-disease and Leqembi demand Biogen's second-quarter profit and revenue beat expectations, helped by strong sales of rare-disease medicines and a 15% rise in Leqembi sales to about $184 million. This shows the core business is growing, which supports the stock.

    This is the main new event of the period and directly explains why Biogen is moving.

  • 2026 profit guidance cut on Apellis charges Biogen slashed its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, largely due to $3.85 per share of acquisition-related charges, including 85 cents from the $5.6 billion Apellis buyout. This weighs on the stock.

    This is the key counterweight that explains why the stock isn't rising more despite the earnings beat.

  • Leqembi real-world data and sales momentum A real-world study showed over 75% of early Alzheimer's patients remained stable on Leqembi, and Q2 sales grew 43% excluding one-time stockpiling. This supports adoption and future sales, a positive for Biogen as Eisai's partner.

    This new evidence reinforces the commercial case for Biogen's key Alzheimer's drug.

  • Pipeline progress: Gazyva priority review, litifilimab enrollment The FDA granted priority review to Gazyva for a rare kidney disease, and Biogen's lupus drug litifilimab completed Phase III enrollment with results due in H2 2026. These advance the pipeline and offer future growth, supporting the stock.

    These are new regulatory and clinical milestones that add to the long-term growth story.

▲3▼1

Leqembi at-home approval lifts Biogen, but diranersen dosing flaw triggers sell-off

  • FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, a once-weekly under-the-skin injection for early Alzheimer's, allowing at-home dosing. This removes the need for IV infusions, which should boost patient demand and sales. Biogen shares rose on the news.

    This is a major new approval that directly expands the market for Biogen's key Alzheimer's drug.

  • Diranersen shows 42% cognitive decline slowdown Biogen presented Phase 2 data showing its tau-targeting drug diranersen slowed cognitive decline by 42% on one measure and cut tau tangles. This suggests a potential new Alzheimer's treatment, lifting hopes for future growth.

    Positive efficacy data from a new drug candidate is a key driver of investor optimism.

  • Dosing paradox clouds diranersen data, stock tumbles The same Phase 2 trial missed its main goal because the lowest dose worked best while higher doses did worse. This unexplained 'dosing paradox' raised doubts about the drug's effectiveness and path forward, causing Biogen shares to fall nearly 9%.

    This negative twist directly caused a sharp sell-off and creates uncertainty about a key pipeline asset.

  • Truist upgrade highlights Alzheimer's pipeline A Truist analyst upgrade pointed to optimism for Biogen's Alzheimer's pipeline, helping the stock gain even as the broader market fell. This analyst view reinforced positive sentiment around the company's Alzheimer's efforts.

    Analyst upgrade is a fresh catalyst that supported the stock price during the period.

Q2 2026
▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

  • RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

    This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

  • FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

    This is a new regulatory win that supports the bull case for Biogen's pipeline.

  • Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

    This is a new negative event that introduces regulatory and legal uncertainty.

  • Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

    This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

June 2026
▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

  • RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

    This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

  • FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

    This is a new regulatory win that supports the bull case for Biogen's pipeline.

  • Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

    This is a new negative event that introduces regulatory and legal uncertainty.

  • Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

    This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

  • RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

    This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

  • FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

    This is a new regulatory win that supports the bull case for Biogen's pipeline.

  • Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

    This is a new negative event that introduces regulatory and legal uncertainty.

  • Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

    This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

© 2026 MarketIVWhy